leavenoone

Ensuring Global Access to Life-Saving Therapies

Global Partner for Named Patient Programs, Early Access & Market Access Solutions.

The challenge is not innovation — it is access.

leavenoone

Patients Are Still Unable to Access Life-Saving Treatments

3 out of 10 patients never start prescribed treatment
50% of patients globally lack access to essential medicines
48% of approved therapies remain unavailable across markets
leavenoone

Five points where access breaks down

Result: Delayed treatment, patient drop-offs, unmet medical need.

01

Complex and fragmented regulatory pathways.

02

Delays in pricing & reimbursement approvals.

03

Lack of structured Named Patient pathways.

04

Limited patient identification systems.

05

No unified coordination across stakeholders.

leavenoone

A Global Named Patient & Access Platform

Unavailability Access Continuity of treatment
01

Named Patient Program

  • Unapproved treatment
  • Off-label use
  • Rare Diseases
02

Managed Access Program

  • Improved Patient Access
  • Efficient Cost Management
  • Increased Transparency
03

Patient Access Schemes

  • Co-Pay Assistance Programs
  • Early Access Programs
  • Compassionate Access Programs
  • Expanded Access Programs
  • Post Trial Access Programs
04

Coverage with Evidence Development

  • Treatment Coverage by tapping payers
  • Data Collection & Study (RWE) on effectiveness and safety
05

Outcome Based Contracts

  • Performance-based risk-sharing model
  • Creation of a product performance model
06

Managed Entry Agreement

  • Marketing Authorization
  • Pricing Strategy Geography Wise
  • Regulatory Lobbying
07

Clinical Trials Support Services

  • Trial Site Identification
  • Trial Site Co-ordination, including Clinical Trial supplies
  • Design, Execution, and Monitoring of Trials
  • Patient Identification and Patient Recruitment
leavenoone

A two-node operating network

Switzerland — HQ

Leave No One AG

  • Strategic leadership
  • Global partnerships
  • Compliance & governance

India — Coordination Office

  • Patient coordination
  • Physician & hospital engagement
  • Market development support
Therapeutic Focus Rare Diseases & Oncology
Geographic Scope Global — EU, LATAM, Asia, Middle East, Africa

Integrated model ensuring Speed, Compliance, and Scalability.

leavenoone

Everything we do starts with the patient

Four brands, one mission — orchestrated around the people we serve.

Patients
leavenoone

Six steps, across borders

1

Patient Identification

2

Physician Engagement

3

Regulatory Pathway Navigation

4

Drug Sourcing & Supply

5

Import & Delivery

6

Treatment Continuity Support

Seamless execution across borders.

leavenoone

Deploying access models tailored to market realities

Compassionate & Early Use

Pre-Approval.

  • Named Patient Programs (NPP)
  • Early Access / Compassionate Use Programs
Pre-Approval

Managed Entry

Bridging to Reimbursement.

  • Managed Access Programs (MAP)
  • Coverage with Evidence Development (CED)
Bridging

Financial & Value Innovation

Post-Approval.

  • Managed Entry Agreements (MEA)
  • Outcome-Based Contracts (OBC)
  • Patient Access Schemes (PAS)
Post-Approval

Customized architectural solutions precisely calibrated to distinct regulatory and payer environments.

One integrator, all stakeholders

Patients Healthcare Providers (HCPs) Payers Policy Makers Patient Advocacy Groups

Actively co-creating pathways across all stakeholders to align incentives and unlock access.

leavenoone

Standard approach vs. Leave No One execution

Standard Industry ApproachLeave No One Execution
Variable StandardsSwitzerland-based governance & credibility
Outsourced & ReactiveDedicated global supply chain
Disconnected Patient PathwaysStrong on-ground coordination
Generalist FocusDeep expertise in rare diseases & oncology
Advisory & Consulting OnlyEnd-to-end execution (not just advisory)

“We don’t just design access — we deliver it.”

leavenoone

Unmatched scale in rare diseases

58,000+ Rare disease patients identified
48+ Countries with active clinical trials conducted
57 International patient identification programs
30+ Active collaborations with orphan drug companies
350+ Peer-reviewed scientific publications
27+ Countries with direct operational presence

A data-driven, globally integrated platform built entirely for execution.

Global Presence

Local teams Global reach

0Offices
0Countries · 45 Markets
0Health Experts

We leave no patient behind, regardless of where they live.

leavenoone

Our goals for every patient

Speed

Reduce time to patient access.

Reach

Enable availability of critical therapies globally.

Empowerment

Support physicians with access pathways.

Efficacy

Improve outcomes in rare diseases & oncology.

Every patient deserves a chance — regardless of geography.

Let’s build access pathways – together

We are redefining how patients access life-saving therapies globally.

Get in Touch